About Us

Who We Are

Established in 2014 as a joint venture between Abu Al Haj Family and Al Faisaliah Group, Axantia develops, manufactures, markets, and distributes high-quality branded generic pharmaceuticals and under-licensed products in 20 countries across the Middle East, Africa, and the CIS.

With the company’s immediate growth, its commitment to meet the healthcare needs of patients becomes even stronger. By providing a broad spectrum of high quality, effective, and affordable pharmaceutical products, Axantia continues to leap towards the betterment of lives one day at a time.

Our Business

Axantia was established to deliver high-quality and affordable medicines, exploit scale, and foresee and respond to new opportunities and risks.

Our subsidiaries – Pharma International Company in Jordan and Madinat Al Dawaa Pharmaceutical Industries in Saudi Arabia are supported by functional organizations with different manufacturing lines to deliver a broad portfolio covering all major therapeutic areas.

Research and development (R&D):

Development of

  1. Oral solid dosage forms
    • Immediate release formulation for General Formulation and Cephalosprins including:
      • Tablets and capsules
      • Dry suspension
    • Modified release formulations:
      • Enteric coated tablets
      • Extended release tablets
  2. Oral liquid forms such as syrups
  3. Cephalosporin powder for injection
  4. Semi solid forms:
    • Ointment
    • Creams

Machinery

  1. Lab scale:
    • Wet granulation suite
    • Tableting
    • Toating
  2. GMP Pilot scale:
    • Wet granulation suite
    • Dry granulation compaction.
    • Tableting monolayer and bilayer
    • Capsule filling
    • Coating
  3. Analytical Research capability:
    • Develop and validate test methods according to latest ICH , EMA and FDA guidelines.
    • Stability testing according ICH guidelines
    • Photostability studies according to ICH guidelines.
    • UHPLC systems with enterprise software solution fully compliant to 21 CFRpt.11
    • Automated dissolution sampling

1. General Formulations Plant

PIC’s main plant covers a total area of about 9,300 m2 that is equipped to produce the following dosage forms:

  • Tablets, Capsules
  • Liquids
  • Creams, Ointment and gels
  •  Suppositories
  • Medicated shampoos


2.
Cephalosporins Plant

IC’s Cephalosporin plant (Unit I&II) covers a total area of 5,000 m2 that is equipped to produce the following dosage forms:

  • Tablets
  • Capsules
  • Dry Suspensions
  • Injections

3. GMP Certificates

  • Jordan
  • Saudi Arabia
  • Ukraine (PICs)
  • GCC
  • Iraq
  • Sudan
  • Yemen
  • Uganda
  • Tanzania
  • Chad
  • Ethiopia
  • Lebanon

4. ISO Certificates

  • 9001
  • 14001
  • 27001:2013

1. General Formulations

Under construction facility that covers a total area of 9,000 m2, will be equipped to produce the following dosage forms:

  • Tablets
  • Capsules
  • Sachets
  • Creams, Ointments, and Gels

 

2. Madinat Al Dawaa has obtained a GMP Certificate from SFDA for secondary packaging of Cephalosporins and GF products

3. Future plans include having an injectable plant in MD

Our Values

Success: Our pursuit is to constantly achieve and accomplish visions and goals we have set. That is why we take a closer look at things, ask questions, and always think ahead.

Accountability: We will always take full responsibility of our tasks and duties, along with their consequences. At Axantia, we honor our commitment to stakeholders and ensure that no task or goal entrusted to us will ever be consciously taken for granted.

Performance: We at Axantia draw on more than savvy and skills; our core values fuel us to be high performers and to make the right decisions. Recognizing that integrity, quality, and leadership make up the company’s soul, we have found the drive to help us perform better and succeed longer.

Quality: Keeping in mind that consumers stake their wellbeing on the quality of our products drives us to produce work of high standard – all the while paying attention to every detail and completing all tasks punctually.

Integrity: Our company, along with our employees, strive to serve as role models by upholding our organizational rules – behaving in public as we would in private by contributing to an environment that does not tolerate ethical deviation. By putting short-term gains in the backburner, the company’s long-term reputation is remains paramount.

Collaboration: Through collaboration and cooperation among our people by championing high performing teams with variance and inclusion, we are able to increase drive and commitment, contributing to the motivation and retention of our employees.

Our Management


With the objective of increasing access to high-quality, affordable medicines, we at Axantia are constantly thinking outside the box and challenging ourselves by boosting our associates’ skills and building a diverse workforce with talented leaders who hold extensive experience in the pharmaceutical industry.

Partnership

Being one of the top 10 key players in the generic pharmaceutical industry in the MENA region, coupled with its in-depth experience and expertise in manufacturing and marketing, Axantia is well-placed to be the partner of choice for companies looking to establish business in this part of the world.

This is for the following reasons:

• Strong local operational infrastructure and expertise across MENA markets
• Financially strong to fund growth and development
• High investment in infrastructure, product development, and human capital
• Continuous growth

We partner with selected pharmaceutical companies to provide access to finished products across the MENA region.